Ocular Therapeutix (OCUL) Income from Continuing Operations (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Income from Continuing Operations of 79452000.0 for Q2 2026, down 18.23% year-over-year from 97163584.66 in Q2 2025, and up 11.79% on a QoQ basis from 90067000.0 in Q1 2026.
Ocular Therapeutix (OCUL) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Income from Continuing Operations for 14 years, with the latest figure at 79452000.0 in Q2 2026.
- Income from Continuing Operations for Q2 2026 came in at 79452000.0, down 18.23% year-over-year; the trailing twelve-month figure through Jun 2026 was 302739000.0 (down 35.84% YoY), and the FY2025 annual result was 544111000.0, down 44.42% from the prior year.
- Income from Continuing Operations advanced to 79452000.0 in Q2 2026, from 90067000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16868000.0 in Q4 2023 and troughed at 90067000.0 in Q1 2026.
- A 5-year average of 42962333.33 and a median of 40706000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2022, when Income from Continuing Operations gained 10.95%; it then plunged 190.56% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 18358000.0 in 2022, then rose by 8.12% to 16868000.0 in 2023, then plunged by 190.56% to 49011000.0 in 2024, then sank by 33.13% to 65249000.0 in 2025, then decreased by 21.77% to 79452000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 79452000.0 in Q2 2026, 90067000.0 in Q1 2026, and 65249000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -79.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.45 Mn |
| Mar 31, 2026 | -90.07 Mn |
| Dec 31, 2025 | -62.44 Mn |
| Sep 30, 2025 | -67.97 Mn |
| Jun 30, 2025 | -67.20 Mn |
| Mar 31, 2025 | -63.08 Mn |
| Dec 31, 2024 | -56.97 Mn |
| Sep 30, 2024 | -43.57 Mn |
| Jun 30, 2024 | -40.75 Mn |
| Mar 31, 2024 | -40.66 Mn |
| Dec 31, 2023 | -27.06 Mn |
| Sep 30, 2023 | -21.43 Mn |
| Jun 30, 2023 | -21.81 Mn |
| Mar 31, 2023 | -23.75 Mn |
| Dec 31, 2022 | -20.79 Mn |
| Sep 30, 2022 | -23.06 Mn |
| Jun 30, 2022 | -21.54 Mn |
| Mar 31, 2022 | -19.50 Mn |
| Dec 31, 2021 | -15.53 Mn |
| Sep 30, 2021 | -21.18 Mn |